Product Description
Carisbamate is a novel drug with neuromodulator activity that is currently under development for the treatment of epilepsy, diabetic neuropathy and neuralgia. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/17899491/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: SK Life Science
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Colombia, Germany, Greece, Hungary, Israel, Italy, Korea, Mexico, Poland, Portugal, Serbia, Spain, Taiwan, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Lennox Gastaut Syndrome|Seizures
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| YKP509C003 | P3 |
Unknown Status |
Lennox Gastaut Syndrome |
2028-06-15 |
|
| YKP509C003 | P3 |
Recruiting |
Seizures|Lennox Gastaut Syndrome |
2025-06-01 |
95% |
| 2022-001256-42 | P3 |
Active, not recruiting |
Lennox Gastaut Syndrome |
2025-03-07 |
|
| YKP509C002 | P1 |
Completed |
Lennox Gastaut Syndrome |
2022-12-14 |
43% |